The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
about
Current status of PET imaging in Huntington's diseaseNeural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challengesNeuroimaging in Huntington's disease.Cell-based therapies for Huntington's disease.Fetal striatal grafting slows motor and cognitive decline of Huntington's disease.Large-sized Fetal Striatal Grafts in Huntington's Disease Do Stop Growing: Long-term Monitoring in the Florence ExperienceFetal stem cell transplantation: Past, present, and future.Moving stem cells to the clinic: potential and limitations for brain repairTherapeutic advances in Huntington's Disease.Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient.Neonatal desensitization for the study of regenerative medicine.Regenerative cellular therapies for neurologic diseasesStem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence.PET Imaging in Huntington's Disease.Pluripotent stem cells progressing to the clinic.Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.Investigational agents for the management of Huntington's disease.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.A commentary on "Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient"Priming of the Cells: Hypoxic Preconditioning for Stem Cell TherapyDirect Comparison of Rat- and Human-Derived Ganglionic Eminence Tissue Grafts on Motor Function.Restorative Strategies in Movement Disorders: the Contribution of Imaging.Induced neural stem cells as a means of treatment in Huntington's disease.Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations
P2860
Q26768644-896F8BB8-A0D5-4768-B3E7-4650E4574B5DQ26775932-F94B5DD0-30FB-44ED-9630-5924D0A9BC3CQ30834004-0A9FB18E-D5A1-4C0B-9674-368535908C5AQ33849242-D6B8CCFE-9E81-4482-ABDB-9DAFE9D84A70Q34092359-DCD4585C-D75A-4E6D-80AF-7BDBB23F2B8CQ34232374-BB35B6E6-98AD-490C-851F-4E0F56D79BFDQ34232844-E952EF87-76A9-4574-ACAB-44384A537B4AQ34470920-52435815-6C64-49F6-91D7-69765C96683CQ34487604-6B63739E-82F4-49B1-AE68-7AC4EA87E64DQ34608910-C0B3BD17-CA6C-41AF-8D8F-B012DDF851EAQ35620293-5ECB7F6A-6FC8-435A-AB53-63E74D665846Q36522668-699462E7-823B-41AA-A8EE-3161B53BCA96Q37643268-630C86CE-D76C-4A84-B2F6-2DA81797009BQ37652595-7A8F0AC2-5B0D-454B-87BE-33270892F00AQ38168592-8EE6DD74-2447-43D4-924D-88376B2F173FQ38673408-FC7C066A-1F52-4293-A006-C6E3095B4A08Q38747535-E0085976-9CFF-4A31-B575-7C8FB28A2B52Q38897803-53FB5D26-D493-4426-9261-5684CD2109C4Q39031769-DF60ABC3-AD72-4E78-B777-BE962C8BAA57Q39035495-DDB6BC8A-EEA0-4935-BEF9-6BC95C247083Q40559755-401DB069-3896-4FED-A282-74DEE2FDC724Q42267329-F9B281B9-AC42-4A06-9DB2-D58A4FE4371DQ45292363-6657BCA5-840D-4E27-851A-2803DF0E18CBQ46109283-F515D5BD-944D-45E2-A76B-F46475040420Q47651159-76141051-1044-4D7D-AF38-E899D91865C2Q58577349-8C04D391-6810-4553-8E79-824F43274CBA
P2860
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The long-term safety and effic ...... moderate Huntington's disease
@ast
The long-term safety and effic ...... moderate Huntington's disease
@en
The long-term safety and effic ...... moderate Huntington's disease
@nl
type
label
The long-term safety and effic ...... moderate Huntington's disease
@ast
The long-term safety and effic ...... moderate Huntington's disease
@en
The long-term safety and effic ...... moderate Huntington's disease
@nl
prefLabel
The long-term safety and effic ...... moderate Huntington's disease
@ast
The long-term safety and effic ...... moderate Huntington's disease
@en
The long-term safety and effic ...... moderate Huntington's disease
@nl
P2093
P2860
P50
P356
P1476
The long-term safety and effic ...... moderate Huntington's disease
@en
P2093
Adrian Carpenter
Carrie Hurrelbrink
Colin Watts
Emma Smith
John D Pickard
NEST-UK collaboration
Paola Piccini
Rachel A Swain
Raj Mathur
P2860
P304
P356
10.1136/JNNP-2012-302441
P407
P50
P577
2013-01-23T00:00:00Z